Form 4: Imunon Director Donald P. Braun Reports Acquisition of Options in Lieu of Cash Compensation

Director Donald P. Braun reports acquiring options to purchase 9,072 shares of Imunon common stock in lieu of cash board fees.

Summary

• On September 10, 2024, Donald P. Braun, a director of Imunon, Inc., filed a Form 4 with the SEC.
• The filing reports the acquisition of options to purchase 9,072 shares of Imunon common stock.
• These options were granted on September 6, 2024, in lieu of cash compensation for board fees.
• The exercise price of the options is $1.04 per share, which represents the closing price of Imunon common stock on the grant date.
• The options vest in three tranches: 1/2 on the date of grant, 1/4 on the one-year anniversary, and 1/4 on the two-year anniversary of the grant date.
• The options expire on September 6, 2034.
• Following the reported transaction, Braun directly owns 28,905 shares of Imunon common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to director compensation. The option grant aligns director interests with shareholders, which is mildly positive.

Positives

• The acquisition of options by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.
• Granting options in lieu of cash preserves the company's cash reserves.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's continued investment in the company's future.

Comparison to Industry Standards

• Option grants to board members are a common practice across the biotechnology industry, often used as a component of their compensation packages.
• The vesting schedule of the options (1/2 on grant, 1/4 annually for two years) is a fairly standard vesting arrangement.

Stakeholder Impact

• Shareholders may view the option grant as a positive sign, aligning the director's interests with the company's performance.
• The company benefits from preserving cash by granting options instead of cash compensation.

Key Dates

Keywords

Form 4, Imunon, Director, Options, Beneficial Ownership, Compensation, IMNN